26-Apr-2024
Barclays Sticks to Their Buy Rating for Revance Therapeutics (RVNC)
TipRanks (Tue, 23-Apr 5:59 AM ET)
OPI, RVNC and AQST are among after hour movers
Seeking Alpha News (Mon, 22-Apr 4:53 PM ET)
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting
Business Wire (Fri, 12-Apr 8:00 AM ET)
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Wed, 27-Mar 4:05 PM ET)
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
Business Wire (Mon, 4-Mar 9:25 AM ET)
Revance Announces Proposed Public Offering of Common Stock
Business Wire (Mon, 4-Mar 6:37 AM ET)
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
Business Wire (Wed, 28-Feb 4:05 PM ET)
Business Wire (Wed, 21-Feb 8:01 AM ET)
Revance to Participate in Upcoming Investor Conferences
Business Wire (Wed, 21-Feb 8:00 AM ET)
Business Wire (Fri, 2-Feb 8:00 AM ET)
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Revance Therapeutics trades on the NASDAQ stock market under the symbol RVNC.
As of April 26, 2024, RVNC stock price climbed to $3.40 with 2,192,940 million shares trading.
RVNC has a beta of 1.66, meaning it tends to be more sensitive to market movements. RVNC has a correlation of 0.06 to the broad based SPY ETF.
RVNC has a market cap of $354.33 million. This is considered a Small Cap stock.
Last quarter Revance Therapeutics reported $70 million in Revenue and -$.62 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.10.
In the last 3 years, RVNC stock traded as high as $37.98 and as low as $3.21.
The top ETF exchange traded funds that RVNC belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
RVNC has underperformed the market in the last year with a price return of -89.2% while the SPY ETF gained +27.4%. RVNC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -43.0% and -17.7%, respectively, while the SPY returned +4.6% and -0.5%, respectively.
RVNC support price is $3.15 and resistance is $3.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RVNC stock will trade within this expected range on the day.